Teva Pharmaceuticals – Recall of Amikacin Injection

- On July 29, 2016, Teva Pharmaceuticals announced a consumer-level recall of some lots of amikacin injection due to the presence of glass particulate matter.
  - The use of or exposure to the recalled product may cause adverse health consequences, and the probability of serious adverse health consequences is likely low.
- The recalled lots (listed below) were shipped beginning July 10, 2015.

Product Description	NDC #	Lot #	Expiration Date
Amikacin sulfate injection, 500 mg/2 mL (250 mg/mL)	00703-9032-03	7080315, 7400315, 7410315	3/2017
		7980415	4/2017
Amikacin sulfate injection, 1 g/ 4 mL (250 mg/mL)	00703-9040-03	2381114, 2771114	11/2016
		4760915	9/2017

- Amikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including *Pseudomonas* species, *Escherichia coli*, species of indole-positive and indole-negative *Proteus*, *Providencia* species, *Klebsiella-Enterobacter-Serratia* species and *Acinetobacter* (*Mima-Herellea*) species.
- Anyone with recalled product should immediately discontinue distributing or dispensing any units from the recalled lots and contact Inmar at **800-967-5952** for return information.
- For medical-related questions, contact Teva at **888-838-2872**.

Action Plan

- Clinical Services will conduct mailings to member(s) that may be affected by the amikacin injection recall, and to providers who prescribed for the drug recently.
- Information regarding the amikacin injection recall will be posted on the optumrx.com portals.